The low-dose and long-course RTX regimen should be recommended for elderly patients with IMN, and the percentage of eosinophilic granulocytes is a better risk predictor of infections after 1 month RTX used in older patients with IMN compared to the percentage of CD19+ B lymphocytes. Here, CD19 is linked to infection.